NPS Pharmaceuticals PT Raised to $39.00 at MLV Capital (NPSP)
Stock analysts at MLV Capital upped their price objective on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $18.00 to $39.00 in a report issued on Thursday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. MLV Capital’s price objective would indicate a potential upside of 27.24% from the stock’s previous close.
NPSP has been the subject of a number of other recent research reports. Analysts at Summer Street raised their price target on shares of NPS Pharmaceuticals from $33.00 to $39.00 in a research note to investors on Wednesday, October 9th. They now have a “buy” rating on the stock. Separately, analysts at Merrill Lynch initiated coverage on shares of NPS Pharmaceuticals in a research note to investors on Thursday, October 3rd. They set a “buy” rating and a $46.00 price target on the stock. Finally, analysts at Wedbush set a $43.00 price target on shares of NPS Pharmaceuticals in a research note to investors on Thursday, October 3rd. They now have an “outperform” rating on the stock. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $35.74.
NPS Pharmaceuticals (NASDAQ:NPSP) traded up 0.20% during mid-day trading on Thursday, hitting $30.65. The stock had a trading volume of 1,180,695 shares. NPS Pharmaceuticals has a 52 week low of $7.35 and a 52 week high of $35.72. The stock has a 50-day moving average of $29.89 and a 200-day moving average of $19.64. The company’s market cap is $3.109 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.06. The company had revenue of $36.50 million for the quarter, compared to the consensus estimate of $31.62 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was down 31.8% on a year-over-year basis. Analysts expect that NPS Pharmaceuticals will post $-0.21 EPS for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.